CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations-Reference-Cited by-同舟云学术

CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations

Published:2020-03 Issue: Volume:127 Page:160-172
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Felip Enriqueta,Ardizzoni Andrea,Ciuleanu Tudor,Cobo Manuel,Laktionov Konstantin,Szilasi Maria,Califano Raffaele,Carcereny Enric,Griffiths Richard,Paz-Ares Luis,Duchnowska Renata,Garcia Miriam Alonso,Isla Dolores,Jassem Jacek,Appel Wiebke,Milanowski Janusz,Van Meerbeeck Jan P.,Wolf Juergen,Li Ang,Acevedo Angelic,Popat Sanjay

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. SEER cancer statistics review, 1975–2015;Noone,1975

2. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Planchard;Ann Oncol,2018

3. Lung cancer in the era of precision medicine;Politi;Clin Cancer Res,2015

4. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016

5. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable?;Scartozzi;Lung Cancer,2010

Cited by 126 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and validation of a new tool to estimate early mortality in patients with advanced cancer treated with immunotherapy;2024-07-16

2. Immunotherapy in non-small cell lung cancer: current status, advances and challenges;Minerva Respiratory Medicine;2024-07

3. Pneumonitis Incidence in Patients With Metastatic Non-small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis;Cureus;2024-07-01

4. Risk and safety profile in checkpoint inhibitors on non-small-cell lung cancer: A systematic review;Human Vaccines & Immunotherapeutics;2024-06-27

5. Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials;Cancers;2024-06-14